ELIDEL ® Pimecrolimus

ELIDEL ® is a Pimecrolimus based drug

THERAPEUTIC GROUP: Other dermatological preparations

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ELIDEL ® Pimecrolimus

ELIDEL ® is indicated in the treatment of atopic dermatitis that is not responsive to corticosteroids or in cases where topical corticosteroid therapy is not recommended.

Mechanism of action ELIDEL ® Pimecrolimus

ELIDEL ® is a medicinal product based on Pimecrolimus, a lipophilic macrolactant derivative of ascomycin, with a strong anti-inflammatory power, comparable to that of highly active corticosteroids.

Unlike the latter, however, Pimecrolimus is generally safer, significantly reducing the risk of skin atrophy and local adverse reactions, and is significantly less absorbable than corticosteroids following topical and therefore potentially less dangerous application.

Its therapeutic activity is instead linked to the ability to inhibit calcium dependent calcineurin phosphatase, an enzyme particularly expressed in T lymphocytes and responsible for the synthesis of inflammatory mediators such as inflammatory cytokines, thus ensuring a significant reduction in inflammatory stimulus and a clear and rapid improvement of clinical symptoms.

Studies carried out and clinical efficacy

PIMECROLIMUS AND ATOPIC ECZEMA

Expert Opin Drug Metab Toxicol. 2013 Jul 22. [Epub ahead of print]

Study that characterizes the utility and safety of Pimecrolimus, reiterating the utility of this drug as an alternative therapeutic approach to that of corticosteroids in patients suffering from atopic eczema, in light of the reduced side effects.

PIMECROLIMUS IN THE TREATMENT OF SEGMENTAL VITILIGINE

Ann Dermatol. 2013 May; 25 (2): 168-72. doi: 10.5021 / ad.2013.25.2.168. Epub 2013 May 10.

Pilot study demonstrating the usefulness of Pimecrolimus in the treatment of segmental vitiligo in pediatric patients, resulting very effective and very well tolerated.

PIMECROLIMUS IN THE TREATMENT OF LICHEN NITIDUS

J Dermatol. 2013 Jun; 40 (6): 499-500. doi: 10.1111 / 1346-8138.12089. Epub 2013 Apr 3.

Clinical case that reports the success of topical treatment with Pimecrolimus-based creams in the treatment of penile Lichen nitidus, describing an excellent tolerability and efficacy.

Method of use and dosage

ELIDEL ®

Pimecrolimus cream for cutaneous use of 10 mg per 1 gr of cream.

The definition of the dosing schedule and the relative dosages is up to the dermatologist doctor expert in the treatment of atopic dermatitis.

In general, adults should be advised to apply the appropriate amount of cream directly to the region affected by the inflammatory process twice a day, taking care to massage the area until the product is completely absorbed.

Warnings ELIDEL ® Pimecrolimus

Therapy with ELIDEL ® must necessarily be preceded by a careful medical examination to assess the patient's overall health and the possible presence of contraindications to the use of this drug.

More precisely, the drug should not be used in patients with immunodeficiencies, infectious atopic dermatitis or in patients with potentially malignant lesions.

The patient should also comply with all the appropriate instructions to limit the occurrence of potential side effects by consulting your doctor immediately following the incidence of unwanted adverse reactions.

It should be remembered that prolonged use of topical products can significantly increase the risk of clinically relevant adverse reactions, especially following the use of occlusive bandages, contraindicated in the case of ELIDEL ®.

PREGNANCY AND BREASTFEEDING

The use of ELIDEL ® is generally contraindicated in pregnancy and in the subsequent period of breastfeeding, given the absence of studies able to fully characterize the safety profile of the drug for the health of the fetus and infant.

Interactions

Considering the low systemic absorption of Pimecrolimus it is possible to define as rare possible pharmacological interactions worthy of clinical note, given also the absence of studies oriented to this characterization.

Contraindications ELIDEL ® Pimecrolimus

The use of ELIDEL ® is contraindicated in patients hypersensitive to the active ingredient or to one of its excipients and in the various cases defined in the warnings.

Undesirable effects - Side effects

The use of ELIDEL ®, especially if continued for a long time, could determine the appearance of local adverse reactions such as folliculitis, boils, infectious dermatitis, burning, irritation and itching.

Fortunately, the various side effects of clinical relevance are rarer.